Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03126318 · ClinicalTrials.gov registry record · Phase 1
A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT03126318 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 32 participants.
The verdict
NCT03126318, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of a single dose of the study drug or placebo administered subcutaneously to patients with moderate-to-severe chronic kidney disease and persistent inflammation.
Interventions
- DRUG Placebo
- DRUG COR-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-05-19 |
| Est. Completion | 2019-12-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03126318
The ClinicalTrials.gov registry entry for NCT03126318 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03126318 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03126318 about?
NCT03126318 is a clinical study titled "A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001". This is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of a single dose of the study drug or placebo administered subcutaneously to patients with moderate-to-severe chronic kidney disease and persistent inflammation...
What is the current status of trial NCT03126318?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2017-05-19. Estimated completion is 2019-12-19.
What interventions are being tested in trial NCT03126318?
The interventions under investigation include: Placebo (DRUG), COR-001 (DRUG).
Who is sponsoring clinical trial NCT03126318?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.